ArticleTranslational oncology2026
Integrated single-cell and bulk transcriptomics reveals STAB1 as a novel therapeutic target for ovarian cancer.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The immunosuppressive tumor microenvironment (TME) and intrinsic heterogeneity of ovarian cancer (OC) are primary drivers of therapeutic resistance and mortality. To deconvolute these complex dynamics and identify robust therapeutic targets, this study employed an integrative strategy combining ensemble machine learning algorithms with high-resolution single-cell transcriptomics and experimental validation. Through dual-feature selection (LASSO and SVM-RFE) applied to multi-cohort bulk transcriptomic data, we identified Stabilin-1 (STAB1) as a top-ranked prognostic determinant. Crucially, single-cell analysis of the OC ecosystem redefined the cellular localization of STAB1, revealing its predominant enrichment in LYVE1+ perivascular-like M2 macrophages and a hyper-aggressive, EMT-active tumor subpopulation. Validating these in silico insights, in vitro loss-of-function assays confirmed that STAB1 silencing in OC cell lines (A2780 and SK-OV-3) significantly suppressed cell proliferation, colony formation, and invasion. Collectively, our findings support STAB1 as a pivotal "dual-checkpoint" molecule that bridges the immunosuppressive stroma and the malignant epithelium, highlighting its potential as a novel therapeutic target for dismantling the ovarian cancer ecosystem.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.